netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Trastuzumab found 20 matches

Formulary items 6 matches
Non-formulary items 2 matches
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Trastuzumab Malignant disease and immunosuppression - Trastuzumab - 08.01.05
  Trastuzumab deruxtecan  (Enhertu) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Trastuzumab emtansine  (Kadcyla®)
(S/C injection) 		Malignant disease and immunosuppression - Trastuzumab - 08.01.05
  Cytotoxic Drug Neratinib  (Nerlynx®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Pertuzumab  (Perjeta®) Malignant disease and immunosuppression - Trastuzumab - 08.01.05
  Cytotoxic Drug Tucatinib  (Tukysa®) Malignant disease and immunosuppression - Protein kinase inhibitors - 08.01.05
 
Non Formulary BNF Category
  Trastuzumab deruxtecan  (Enhertu® ) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab  (08.01.05)
link in drug section NICE TA34: Breast cancer - trastuzumab (08.01.05)
link in drug section NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (08.01.05)
link in drug section NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (08.01.05)
link in drug section NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (08.01.05)
link in drug section NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (08.01.05)
link in drug section NICE TA976: Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (08.01.05)
link in drug section NICE TA983: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (08.01.05)
link in drug section TA992: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (08.01.05)

SubSection Titles / notes  
Trastuzumab - (08.01.05)

 
netFormulary